Candel Therapeutics IncNASDAQ:CADL
- LAST PRICE6.1500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots6.1100/ 1
- Ask / Lots6.1400/ 1
- Open / Previous Close5.9600 / 6.1500
- Day Range
- 52 Week Range
- Volume452,489
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CADL |
|---|---|---|
| 09:32 ET | 3043 | 5.952 |
| 09:36 ET | 1700 | 6.02 |
| 09:39 ET | 3194 | 6.04 |
| 09:41 ET | 5014 | 5.91 |
| 09:43 ET | 35925 | 5.92 |
| 09:48 ET | 300 | 5.9287 |
| 09:52 ET | 100 | 6.01 |
| 09:54 ET | 1000 | 6 |
| 09:56 ET | 2793 | 6.01 |
| 09:57 ET | 949 | 5.9916 |
| 10:01 ET | 3664 | 5.975 |
| 10:03 ET | 1087 | 5.97 |
| 10:06 ET | 520 | 5.985 |
| 10:08 ET | 500 | 5.96 |
| 10:12 ET | 1900 | 5.92 |
| 10:14 ET | 964 | 5.9 |
| 10:15 ET | 275 | 5.93 |
| 10:17 ET | 100 | 5.96 |
| 10:19 ET | 500 | 5.98 |
| 10:21 ET | 300 | 5.9401 |
| 10:24 ET | 17510 | 6.05 |
| 10:26 ET | 400 | 6.07 |
| 10:28 ET | 200 | 6.1 |
| 10:30 ET | 1126 | 6.08 |
| 10:32 ET | 500 | 6.1 |
| 10:33 ET | 1700 | 6.13 |
| 10:35 ET | 3549 | 6.1 |
| 10:37 ET | 100 | 6.07 |
| 10:39 ET | 700 | 6.0702 |
| 10:42 ET | 145 | 6.0701 |
| 10:44 ET | 100 | 6.1 |
| 10:46 ET | 601 | 6.12 |
| 10:53 ET | 102 | 6.125 |
| 10:55 ET | 3370 | 6.185 |
| 10:57 ET | 1930 | 6.1928 |
| 11:00 ET | 400 | 6.2 |
| 11:04 ET | 100 | 6.19 |
| 11:06 ET | 1550 | 6.13 |
| 11:08 ET | 350 | 6.13 |
| 11:11 ET | 200 | 6.1009 |
| 11:13 ET | 500 | 6.1275 |
| 11:15 ET | 415 | 6.1 |
| 11:18 ET | 3250 | 6.105 |
| 11:24 ET | 1250 | 6.06 |
| 11:26 ET | 1885 | 6.03 |
| 11:27 ET | 20428 | 6.07 |
| 11:29 ET | 15950 | 6.08 |
| 11:31 ET | 957 | 6.085 |
| 11:33 ET | 466 | 6.07 |
| 11:36 ET | 7880 | 6.09 |
| 11:38 ET | 900 | 6.07 |
| 11:40 ET | 100 | 6.08 |
| 11:42 ET | 1200 | 6.075 |
| 11:44 ET | 848 | 6.105 |
| 11:45 ET | 981 | 6.09 |
| 11:47 ET | 2000 | 6.08 |
| 11:51 ET | 100 | 6.07 |
| 11:54 ET | 600 | 6.04 |
| 11:56 ET | 1000 | 6.035 |
| 11:58 ET | 100 | 6.01 |
| 12:02 ET | 200 | 6.03 |
| 12:03 ET | 200 | 6.03 |
| 12:05 ET | 778 | 6.03 |
| 12:16 ET | 750 | 6 |
| 12:18 ET | 1265 | 6.02 |
| 12:20 ET | 100 | 6.04 |
| 12:27 ET | 100 | 6.035 |
| 12:32 ET | 111 | 6.04 |
| 12:38 ET | 1130 | 6.02 |
| 12:39 ET | 600 | 6 |
| 12:43 ET | 200 | 6 |
| 12:45 ET | 450 | 6 |
| 12:48 ET | 100 | 6 |
| 12:50 ET | 100 | 6.01 |
| 12:57 ET | 3000 | 6.02 |
| 12:59 ET | 1027 | 6.02 |
| 01:01 ET | 522 | 6 |
| 01:03 ET | 970 | 6.01 |
| 01:08 ET | 1114 | 6 |
| 01:10 ET | 200 | 6.01 |
| 01:15 ET | 100 | 6 |
| 01:17 ET | 1475 | 6.01 |
| 01:24 ET | 150 | 6.01 |
| 01:28 ET | 100 | 6 |
| 01:30 ET | 300 | 6 |
| 01:32 ET | 200 | 6 |
| 01:33 ET | 500 | 6 |
| 01:35 ET | 595 | 6 |
| 01:37 ET | 1645 | 6.03 |
| 01:39 ET | 100 | 6.04 |
| 01:42 ET | 683 | 6.04 |
| 01:46 ET | 8433 | 6.045 |
| 01:48 ET | 500 | 6.03 |
| 01:57 ET | 200 | 6 |
| 02:02 ET | 200 | 6.04 |
| 02:09 ET | 500 | 6.03 |
| 02:11 ET | 600 | 6.03 |
| 02:13 ET | 30058 | 5.93 |
| 02:15 ET | 3420 | 5.95 |
| 02:18 ET | 300 | 5.95 |
| 02:20 ET | 300 | 5.91 |
| 02:27 ET | 300 | 5.91 |
| 02:29 ET | 300 | 5.91 |
| 02:33 ET | 300 | 5.93 |
| 02:36 ET | 3483 | 5.98 |
| 02:38 ET | 100 | 5.975 |
| 02:40 ET | 2100 | 5.99 |
| 02:42 ET | 700 | 5.96 |
| 02:44 ET | 765 | 5.955 |
| 02:45 ET | 100 | 5.97 |
| 02:47 ET | 100 | 5.99 |
| 02:56 ET | 100 | 5.98 |
| 02:58 ET | 316 | 5.98 |
| 03:00 ET | 100 | 5.96 |
| 03:02 ET | 1037 | 5.99 |
| 03:03 ET | 400 | 5.94 |
| 03:05 ET | 11128 | 5.88 |
| 03:07 ET | 2000 | 5.91 |
| 03:09 ET | 3955 | 5.98 |
| 03:12 ET | 5635 | 5.99 |
| 03:14 ET | 2580 | 6.03 |
| 03:16 ET | 250 | 6 |
| 03:18 ET | 677 | 5.96 |
| 03:20 ET | 270 | 5.96 |
| 03:21 ET | 371 | 5.96 |
| 03:23 ET | 300 | 5.94 |
| 03:25 ET | 100 | 5.94 |
| 03:27 ET | 100 | 5.93 |
| 03:32 ET | 999 | 5.97 |
| 03:34 ET | 1825 | 5.99 |
| 03:36 ET | 1040 | 6.02 |
| 03:38 ET | 29404 | 6.12 |
| 03:39 ET | 27857 | 6.12 |
| 03:41 ET | 8200 | 6.08 |
| 03:43 ET | 5047 | 6.06 |
| 03:45 ET | 7497 | 6.095 |
| 03:48 ET | 2804 | 6.095 |
| 03:50 ET | 4119 | 6.08 |
| 03:52 ET | 4661 | 6.1 |
| 03:54 ET | 5678 | 6.08 |
| 03:56 ET | 7970 | 6.11 |
| 03:57 ET | 9141 | 6.12 |
| 03:59 ET | 14350 | 6.15 |
Jun 18, 2024
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference, from 8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 18, 2024 by Dow Jones
Jun 11, 2024
Candel Therapeutics to Join Russell 3000(R) Index, from 8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
8:00AM ET on Tuesday Jun 11, 2024 by Dow Jones
Jun 3, 2024
May 30, 2024
DJ Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment, from 8:30AM ET on Thursday May 30, 2024 by Dow Jones
8:30AM ET on Thursday May 30, 2024 by Dow JonesFDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma, from 8:00AM ET on Thursday May 30, 2024 by Dow Jones
8:00AM ET on Thursday May 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Candel Therapeutics Inc | 179.7M | -4.8x | --- |
Outlook Therapeutics Inc | 178.6M | -0.6x | --- |
Ventyx Biosciences Inc | 177.0M | -0.8x | --- |
Achieve Life Sciences Inc | 170.7M | -3.7x | --- |
Biomea Fusion Inc | 189.1M | -1.6x | --- |
X4 Pharmaceuticals Inc | 169.6M | -1.4x | --- |
Company Information
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.
Contact Information
- Headquarters
- 117 Kendrick Street,, Suite 450NEEDHAM, MA, United States 02494
- Phone
- 617-916-5445
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Manning
- President, Chief Executive Officer, Director
- Paul Tak
- Interim Chief Financial Officer
- Charles Schoch
- Chief Scientific Officer
- Francesca Barone
- Vice President - Development Leader
- Christopher Matheny
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $179.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 29.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.29 |
Book Value | $0.44 |
P/E Ratio | -4.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
